Similar articles

• p53 mutation in hepatocellular carcinoma and chronic liver disease.

  Ceyhan K, Akpolat I, Bozdoğan N, Kobat I, Ekinci C. Ceyhan K, et al. Am J Gastroenterol. 1996 Jul;91(7):1476-7. Am J Gastroenterol. 1996. PMID: 8678035 No abstract available.
• T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection.

  Ito K, Tanaka Y, Orito E, Sugiyama M, Fujiwara K, Sugauchi F, Kato T, Tokita H, Izumi N, Kato M, Yuen MF, Lai CL, Gish RG, Ueda R, Mizokami M. Ito K, et al. Clin Infect Dis. 2006 Jan 1;42(1):1-7. doi: 10.1086/498522. Epub 2005 Nov 29. Clin Infect Dis. 2006. PMID: 16323084
• Non-sequencing molecular approaches to identify preS2-defective hepatitis B virus variants proved to be associated with severe liver diseases.

  Raimondo G, Costantino L, Caccamo G, Pollicino T, Squadrito G, Cacciola I, Brancatelli S. Raimondo G, et al. J Hepatol. 2004 Mar;40(3):515-9. doi: 10.1016/j.jhep.2003.11.025. J Hepatol. 2004. PMID: 15123368
• Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology.

  Chen CJ, Chen DS. Chen CJ, et al. Hepatology. 2002 Nov;36(5):1046-9. doi: 10.1053/jhep.2002.37084. Hepatology. 2002. PMID: 12395312 Review. No abstract available.
• [Clinical and molecular correlation between chronic hepatitis and hepatocellular carcinoma induced by hepatitis B virus].

  Shapiro IIa, Shabrov AV, Karev VE, Leenman EE, Kvetnoĭ IM, Tsinzerling VA, Sologub TV. Shapiro IIa, et al. Arkh Patol. 2005 Mar-Apr;67(2):6-10. Arkh Patol. 2005. PMID: 15938110 Review. Russian.